P Paschka
Overview
Explore the profile of P Paschka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlenk R, Weber D, Herr W, Wulf G, Salih H, Derigs H, et al.
Leukemia
. 2019 Feb;
33(8):1923-1933.
PMID: 30728457
The aim of this randomized phase-II study was to evaluate the effect of substituting cytarabine by azacitidine in intensive induction therapy of patients with acute myeloid leukemia (AML). Patients were...
2.
Nagel G, Weber D, Fromm E, Erhardt S, Lubbert M, Fiedler W, et al.
Ann Hematol
. 2017 Nov;
96(12):1993-2003.
PMID: 29090343
We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in...
3.
Gaidzik V, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, et al.
Leukemia
. 2017 Jun;
32(1):30-37.
PMID: 28643785
We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-R882H/-R882C mutations (DNMT3A). MRD was determined by real-time quantitative PCR (RQ-PCR)...
4.
Wattad M, Weber D, Dohner K, Krauter J, Gaidzik V, Paschka P, et al.
Leukemia
. 2017 Feb;
31(6):1306-1313.
PMID: 28138160
We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324 patients with newly diagnosed...
5.
Schlenk R, Frech P, Weber D, Brossart P, Horst H, Kraemer D, et al.
Leukemia
. 2017 Jan;
31(5):1217-1220.
PMID: 28096533
No abstract available.
6.
Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik V, et al.
Leukemia
. 2017 Jan;
31(4):1012-1015.
PMID: 28090090
No abstract available.
7.
Thol F, Klesse S, Kohler L, Gabdoulline R, Kloos A, Liebich A, et al.
Leukemia
. 2016 Nov;
31(6):1286-1295.
PMID: 27881874
We studied acute myeloid leukemia (AML) patients with lympho-myeloid clonal hematopoiesis (LM-CH), defined by the presence of DNA methyltransferase 3A (DNMT3A) mutations in both the myeloid and lymphoid T-cell compartment....
8.
Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, et al.
Leukemia
. 2016 Nov;
30(11):2282.
PMID: 27804971
No abstract available.
9.
Theis F, Corbacioglu A, Gaidzik V, Paschka P, Weber D, Bullinger L, et al.
Leukemia
. 2016 Jul;
30(11):2248-2250.
PMID: 27375010
No abstract available.
10.
Gaidzik V, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, et al.
Leukemia
. 2016 May;
30(11):2160-2168.
PMID: 27137476
We evaluated the frequency, genetic architecture, clinico-pathologic features and prognostic impact of RUNX1 mutations in 2439 adult patients with newly-diagnosed acute myeloid leukemia (AML). RUNX1 mutations were found in 245...